Payer Implications of the 2014 Clinical Updates on Hematologic Malignancies for Hematology/Oncology and Managed Care Professionals
Expert Insights on Data Presented at the 2014 NCCN Annual Congress on Hematologic Malignancies
| FACULTY CONTRIBUTORS | ||||||||||||
|
||||||||||||
 |
||||||||||||
TARGET AUDIENCE
This activity has been designed to meet the educational needs of community hematologists/oncologists, the extended hematology/oncology care team including pathologists, radiologists, nurse practitioners, oncology nurses, oncology pharmacists, case managers, and patient navigators, as well as managed care professionals involved in the care of patients with hematologic malignancies.
STATEMENT OF NEED/PROGRAM OVERVIEW
There is a documented need to provide both hematology/oncology clinicians and managed care decision-makers with insights regarding the clinical and economic value of targeted cancer treatments for hematologic cancer patients. As cancer care becomes increasingly “personalized,” managed care decision makers struggle to design effective benefit plans that continue to advance the needs of the “majority” (their membership). Hematologists/oncologists, working with individual cancer patients, struggle to choose treatments that are effective, while minimizing toxicities and the financial risk for both patients and the health care system. For both parties, the fast pace of new product development and lack of comprehensive and comparative clinical data will only continue to compound the challenges associated with decision making.
Using common hematologic cancer diagnoses – multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL) – as examples, the proposed educational program for managed care professionals will feature practical discussions and demonstrations of current and emerging clinical data, pharmacy benefit design options, and resource management resources. Thought leaders and managed care experts will report and discuss key data presented at the 2014 NCCN Annual Meeting and will evaluate and recommend innovative strategies that will enhance the knowledge and competency of managed care professionals who are striving to optimize both cost-efficiency and treatment outcomes for cancer patients.
For community-based hematologists/oncologists, the proposed educational program will explore current and emerging data in some of the most common patient subsets in the spectrum of hematologic malignancies. Academic and community-based experts will review and interpret the latest clinical data for new and investigational targeted agents for MM, CLL, and MCL; explain the recommendations and gaps associated with current published treatment guidelines; and exemplify important learnings through patient case vignettes. Managed care expects will discuss their current and future approaches for managed care organizations (MCO) reimbursement of mutation testing and medical treatments, as well as spotlight the support services that MCOs provide to reinforce hematologists’/oncologists’ patient education and compliance efforts.
Learning Goal/Purpose
This educational initiative is designed to provide hematology/oncology and managed care professionals with the latest clinical data, pharmacy benefit design options, and resource management resources to optimize both cost-efficiency and treatment outcomes for cancer patients.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
ACCREDITATION
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Medical Education Resources designated this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Credit
|
|
 |
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number – 0816-9999-15-044-H01-P This activity is certified as knowledge-based CPE. |
Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.0 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.
DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Faculty | Reported Financial Relationship |
| Jeffrey D. Dunn, PharmD, MBA | Consulting Fees: Genentech, Inc. |
| Michael Fine, MD | No financial relationships to disclose |
| Sergio Giralt, MD | Consulting Fees: Amgen, Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Ltd. Grants/Research Support: Celgene Corporation, Onyx Pharmaceuticals, Inc., Takeda Pharmaceutical Company Ltd. |
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Content Manager | Reported Financial Relationship |
| Steven Casebeer, MBA | No financial relationships to disclose |
| Lauren Light, PharmD | No financial relationships to disclose |
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this activity. During the period March 2015 through September 30, 2016, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question and obtaining a score of 70% or higher, 4) complete the evaluation form.
A statement of credit will be issues only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.com within 4 weeks.
MEDIA
Internet
DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, Bristol-Myers Squibb, and/or Takeda Oncology. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Impact Education, LLC, Bristol-Myers Squibb, and/or Takeda Oncology. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
FEE INFORMATION
There is no fee for this educational activity.
